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Title of study:  A protocol for an observational study for finasteride 5mg in men 
with moderate Benign Prostatic Hyperplasia 
Phase: Observational study 
Investigational Product: Finasteride 5mg 
Indication:Benign Prostatic Hyperplasia 
Primary Efficacy Endpoint :The primary efficacy endpoint of the study will be 
the change in IPSS from baseline to month 24 because of taking Finasteride 5mg. 
Secondary Efficacy Endpoint: The secondary efficacy endpoints will be the 
categorical improvements in IPSS ( >=3 points or >=25%) and the time to, and 
proportion of, patients with clinical progression of BPH {rise in total IPSS of >=3 
points compared with baseline, BPH-related AUR, recurrent UTI, overflow or urge 
incontinence or renal insufficiency (single >=50% rise from baseline serum 
creatinine and total value >=1.5mg/dl)}.Health outcomes will be include change in 
BII score from baseline; rating of IPSS-Q8; and responses to two questions of the 
PPST questionnaire 
 
Primary Safety Objective: To determine the development of Adverse Events 
and Serious Adverse Events because of receiving Finasteride. 
Study Design and Duration: This is a non-interventional observational study to 
evaluate the efficacy and safety of finasteride in men with BPH. The study will be 
event driven thus the number of subjects required and length of treatment are best 
estimates based on event rates in similar studies. The expected duration of the 
study, from first subject, first visit through the last follow up phone contact for the 
last subject is approximately 24 months. 
 Patients will visit the clinic 1 month after the first visit and then every 4 
months until the end of the study period. Patient-reported symptoms, symptom 
impact, BPH-related QoL (Quality of Life), and treatment satisfaction were 
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assessed using the IPSS, BPH Impact Index (BII) score, question 8 of the IPSS 
(IPSS-Q8; ‘if you were to spend the rest of your life with your urinary condition 
just the way it is now, how would you feel about that?’), and patient perception of 
study treatment (PPST) at every visit. 
Data on AEs (Adverse Events) were collected from the time of 
administration of the first study treatment dose until discontinuation. 
 
Study Population:The study population will be men with particular criteria  
  Inclusion criteria 
1. men aged >=50 years 
2. confirmed clinical diagnosis of BPH and moderate LUTS (IPSS 8-19)  
3. Prostate Volume >= 30ml by TRUS (at screening) 
4. Serum prostate-specific antigen (PSA) level >=1.5 ng/ml 
 
Exclusion criteria 
1. Evidence or suggestion of prostate cancer 
2. Neurogenic bladder dysfunction 
3. History of acute urinary retention necessitating two or more 
catheterizations in the previous 2 years 
4. History of prostate surgery or other invasive procedure  (e.g. 
transurethral microwave thermotherapy, urethral stenting ,balloon 
urethroplasty) 
5. History of condition predisposing patient to urethral strictures 
6. Chronic bacterial prostatitis 
7. Total serum PSA level of >10ng/ml 
8. Use of drugs with antiandrogenic properties 
9. Hematuria associated with untreated active  urinary tract infection, 
prostatitis or bladder cancer 
10. Current or prior treatment related to BPH 
11. Any condition jeopardizing patient's ability to complete the study 
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Statistical Methods:The statistical test which is going to be used is t-test for 
dependent data (paired samples t-test) with P-value=0.05 (level of significance) in 
IBM SPSS Statistics 22. We are going to observe if there is statistically significant 
difference between mean IPSS in 24th month vs mean IPSS in baseline . In 
addition, we are going to observe if there is statistically significant difference 
between  mean  BII Score 24th month vs BII Score baseline and between mean 
IPSS Q8 24th month vs IPSS Q8 baseline . 
Also ,we are going to observe : 
 the percentage of the patients who will show improvement  >=3 points in 
IPSS or >=25% between 24th month and baseline. 
 the percentage of the patients (and the cardinal number) who will develop 
clinical progression of BPH between 24th month and baseline 
 the percentage of the patients (and the cardinal number) in each category of 
PPST questionaire in the baseline and in the 24th month 
 the percentage of the patients (and the cardinal number) who will develop 
AE, SAE and Adverse Events leading to study/drug discontinuation because 





Institutional Repository - Library & Information Centre - University of Thessaly






UNIT 1: INTRODUCTION 
 
1.1 Backround -BPH 
Benign prostatic hyperplasia (BPH) is characterized  by a proliferation of 
prostatic tissue, particularly in the periurethral zone, leading to anatomic 
obstruction of the urethra and diverse but characteristic urinary tract symptoms. 
 The clinical manifestations of BPH fall into two categories: symptoms of 
obstruction, related to impaired flow (e.g., poor stream, hesitancy or urinary 
retention), and symptoms of irritation, related to alterations in the bladder response 
to filling (e.g., frequency, nocturia or urgency).) Although these symptoms are 
linked to prostate enlargement, the correlation between symptom intensity and the 
degree of prostate enlargement is complex and poorly understood. The presence of 
symptoms does not always correlate with objective measurements of voiding 
function (e.g., maximuin or mean urinary flow rate, prostate volume or residual 
urine volume).  
The natural history of BPH is variable but slowly progressive. Some patients 
tolerate mild to moderate symptoms for a long time without any treatment. 
Nonetheless, symptoms affect quality of life: they are bothersome, interfere with 
daily activities and can affect psychological well-being. Moreover, the serious 
complications of BPH, such as infection, urinary retention and upper tract 
sequelae, may constitute medical emergencies. 
Until recently, the sole treatment for severe symptoms of BPH involved 
surgery (e.g. transurethral resection of the prostate [TURP]), with surveillance 
(watchful waiting) the only alternative. Although TURP is associated with a very 
low mortality rate (0.2%), the morbidity is substantial (18%) and includes failure 
to void (6.5%), postoperative bleeding requiring transfusion (3.9%), clot retention 
(3.3%) and infection (2.3%).9 In addition, following TURP there is a variable 
incidence of urethral stricture, loss of ejaculation (55%) and impotence (13%).  
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Therefore, it is not surprising that many patients who seek treatment for their 
BPH symptoms consider medical therapy before surgery. Two types of medication 
have proven beneficial: ox-adrenergic blockers and 5a-reductase inhibitors. 
 
1.2  5a-reductase inhibitors (5ARIs)-FINASTERIDE 
 
Of the two commonly used pharmacotherapeutic interventions for men with 
symptomatic benign prostatic hyperplasia (BPH), the 5a-reductase inhibitors 
(5ARIs) and a1 blockers, only the 5ARIs have been shown to modify the 
underlying pathology. Data from three large-scale, randomised clinical studies 
demonstrate that treatment with the 5ARIs dutasteride or finasteride results in 
significant reductions in prostate volume associated with improvements in urinary 
symptoms and flow, and significant reductions in the risks of acute urinary 
retention (AUR) and BPH-related surgery. In contrast, a1 blockers, which reduce 
the dynamic elements of BPH but do not reduce prostate volume, are associated 
with rapid improvements in symptoms and flow, but have not been shown to 
reduce the long-term risk of AUR or BPH-related surgery in blinded, randomised 
and placebo-controlled studies. 
BPH is a progressive disease in many men, and underlying this progression 
is continuing prostate growth .Therapy aimed at reducing prostate volume, and the 
accompanying benefits in improving symptoms and lessening the risk of BPH 
morbidity, has a logical place in the medical management of men at risk of 
progressive BPH. However, the long-term nature of BPH requires a therapy that 
reduces and maintains reductions in prostate volume, has lasting effects on 
symptoms and minimizes the risks of AUR and BPH-related surgery. A number of 
studies with the 5ARI finasteride have examined its long-term effect over 4 to 8 
years .These studies demonstrate that finasteride treatment is associated with a 
maximal reduction in prostate volume after 2 years of therapy that is maintained 
without further reductions over the remaining course of the studies. 5ARIs achieve 
reductions in prostate volume through the inhibition of the nuclear-bound steroid 
5a-reductase (5AR) isoenzymes, which chemically reduce testosterone to 
dihydrotestosterone (DHT), the principal androgen stimulating prostatic growth. 
Finasteride suppresses serum DHT by approximately 70%, with only 49% of 
treated men achieving this reduction in one data series . 
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1.3 Information about the drug 
Treating urinary problems caused by an enlarged prostate gland (benign 
prostatic hyperplasia [BPH]). It is also used to lower the risk of needing surgery to 
treat BPH. It may be used with another medicine (doxazosin) to lower the risk of 
worsening BPH. It may also be used for other conditions as determined by your 
doctor. 
Finasteride is a type of steroid reductase inhibitor. It works by reducing the 
amount of the hormone dihydrotestosterone (DHT) in the body. This makes the 
prostate gland smaller, which helps to relieve urinary problems.  
Finasteride is a 5α-reductase inhibitor, specifically the type II and III 
isoenzymes. By inhibiting 5α-reductase, finasteride prevents conversion of 
testosterone to dihydrotestosterone (DHT) by the type II and III isoenzymes, 
resulting in a decrease in serum DHT levels by about 65–70% and in prostate DHT 
levels by up to 85–90%, where expression of the type II isoenzyme dominates. 
Unlike triple inhibitors of all three isoenzymes of 5α-reductase like dutasteride 
which can reduce DHT levels in the entire body by more than 99%, finasteride 
does not completely suppress DHT production because it lacks significant 
inhibitory effects on the 5α-reductase type I isoenzyme, with 100-fold less affinity 
for I as compared to II. In addition to blocking the type II and III isoenzymes, 
finasteride competitively inhibits the 5β-reductase type II isoenzyme, though this is 
not believed to affect androgen metabolism. 
By blocking DHT production, finasteride reduces androgen activity in the 
scalp. In the prostate, inhibition of 5α-reductase reduces prostate volume, which 
improves BPH and reduces risk of prostate cancer. Inhibition of 5α-reductase also 
reduces epididymal weight, and decreases motility and normal morphology of 
spermatozoa in the epididymis. 
DHT helps activate the GABAA receptor, which functions to tamp down 
signaling among neurons; because finasteride prevents the formation of  DHT, it 
may contribute to a reduction of GABAA activity. Reduced GABAA has been 
implicated in depression, anxiety, and sexual dysfunction.  
 
1.4 Non-interventional observational studies 
In a non interventional observational study which examine the safety of 
finasteride as used in general medical practice to treat benign prostatic hypertrophy 
(BPH), the results were impressive. Information was collected on 14 772 patients 
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who were included in an observational cohort study conducted using Prescription- 
Event Monitoring. Finasteride was reported to have been effective in 60% of the 
patients in whom an opinion on efficacy was recorded. Impotence or ejaculatory 
failure was reported in 2.1% of the patients, decreased libido in 1% and 
gynaecomastia and related conditions in 0.4%. Impotence was the most frequent 
reason for stopping treatment with finasteride and was the most commonly 
reported adverse reaction to the drug. Of the patients included in the elderly cohort 
involved in this study, 819 (5.5%) died; none of these deaths was attributed to 
finasteride. As o conclusion impotence or ejaculatory failure, decreased libido and 
gynaecomastia in a small proportion of patients were associated with the use of 
finasteride. The results of this study strongly suggest that this drug is acceptably 
safe when used in accordance with the current prescribing information. 
 In another multicenter, double-blind, placebo controlled study conducted 25 
centers of United States and 5 of Canada they evaluated two doses of finasteride 
(1mg and 5mg) and placebo, each given once daily for 12 months in 895 men with 
prostatic hyperplasia. Urinary symptoms, urinary flow, prostatic volume and serum 
concentrations dihydrotestosterone and PSA were determined periodically during 
the treatment period. As compared with men in the placebo group, the men treated 
with 5mg of finasteride daily had a significant decrease in total urinary symptom-
scores (P<0.001) , an increase of 1.6ml per second (22 percent P<0.001) in the 
maximal urinary flow rate and a 19 percent decrease of prostatic volume 
(P<0.001). The men treated with 1mg of finasteride per day did not have a 
significant decrease in total urinary symptom-scores , but had an increase of 1.4 ml 
per second (23 percent) in the maximal flow rate and 18 percent decrease of 
prostatic volume. The men given placebo had no changes in total urinary 
symptom-scores , an increase of 0.2 ml per second (8 percent) in the maximal 
urinary-flow rate and a 3 percent decrease in prostatic volume. The frequency of 
AE in the tree groups was similar , except of a higher incidence of decreased 
libido, impotence and ejaculatory disorders in finasteride-treated groups. The 
treatment of BPH with finasteride 5mg per day results in a significant decrease in 
symptoms of obstruction, an increase in urinary flow and a decrease in the 
prostatic volume, but a slightly increased risk of sexual dysfunction.  
 
 
Institutional Repository - Library & Information Centre - University of Thessaly




UNIT 2: STUDY OBJECTIVES 
 
2.1 Primary Objective 
To evaluate the efficacy and safety of 2 years treatment of moderate BPH with 
finasteride. 
Efficacy assessments included the International Prostate Symptom Score (IPSS), 
BPH Impact Index (BII) score  and patient perception of study treatment (PPST). 
 




UNIT 3: ETHICAL CONSIDERATIONS 
 
3.1 Good Clinical Practice 
This study will be conducted in accordance with Good Clinical Practice 
(GCP) as defined by the International Conference of Harmonization (ICH) and in 
accordance with the ethical principles underlying  European  Union Directive. 
Furthermore, the study will be conducted in compliance with the protocol. The 
protocol, the amendments of protocol and the subject informed consent will 
receive IRB/IEC approval opinion prior to initiation of the study. 
 
3.2 Informed Consent 
Investigators must ensure that subjects , or, in those situations where consent 
cannot be given by subjects, their legally acceptable representatives, are clearly 
and fully informed about the purpose, potential risks, and other critical issues of 
the study in which they volunteer to participate. Freely given written informed 
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consent must be obtained from every subject or in those situations where consent 
cannot be given by subjects, their legally acceptable representatives. 
Subjects unable to give their written consent may only be enrolled in the 
study with the consent of a legally acceptable representative. The subject must also 
be informed about the nature of the study to the extent compatible with the 
subject’s understanding and should they become capable, personally sign and date 
the consent form as soon as possible. The explicit wish of a subject unable to give 
his or her written consent, who is capable of forming an opinion and assessing this 
information to refuse participation in, or to be withdrawn from, the study at any 
time should be considered by the investigator. 
Subjects may withdraw consent from participation in the study at any time. 
In the event a subject withdraws consent to receive study drug, the site pay (with 
the subject’s agreement) continue to contact the subject, general practitioner and 
any other physician or medical care provider for the collection of outcome and 
survival follow up data. 
 
3.3 Subject Confidentiality 
The Investigators and the Sponsor will preserve the confidentiality of all 
subjects taking part in the study, in accordance with GCP and local regulations. 
The Investigator must ensure that the subject’s anonymity is maintained. On the 
eCRFs or other documents submitted to the Sponsor or the CRO, subjects should 
be identified by a unique subject identifier as designed by the Sponsor. Sponsor 
personnel whose responsibilities require access to personal data should agree to 
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UNIT 4: INVESTIGATION PLAN 
 
4.1 Study Design and duration 
This is a non-interventional observational study to evaluate the efficacy and 
safety of finasteride in men with BPH. The study will be event driven thus the 
number of subjects required and length of treatment are best estimates based on 
event rates in similar studies. The expected duration of the study, from first 
subject, first visit through the last follow up phone contact for the last subject is 
approximately 24 months. 
 Patients will visit the clinic 1 month after the first visit and then every 4 
months until the end of the study period. Patient-reported symptoms, symptom 
impact, BPH-related QoL (Quality of Life), and treatment satisfaction were 
assessed using the IPSS, BPH Impact Index (BII) score, question 8 of the IPSS 
(IPSS-Q8; ‘if you were to spend the rest of your life with your urinary condition 
just the way it is now, how would you feel about that?’), and patient perception of 
study treatment (PPST) at every visit. 
 The IPSS is a seven-item questionnaire that quantitatively measures the 
level of urinary symptoms reported as a total IPSS. The total IPSS can range from 
0 to 35 and classifies BPH symptoms into mild (0–7), moderate (8–19), or severe 
(20–35). 
 An additional, independent eighth question (IPSS-Q8) was added to assess 
self-perceived QoL and BPH-related health status. The IPSS-Q8 score ranges from 
0 to 6 where 0 means ‘delighted’ and 6 means ‘terrible’ life.  
The BII is a four-item questionnaire that measures the impact of urinary 
problems on a subject’s general sense of wellbeing in four domains of health: 
physical discomfort from urinary problems, worry about health because of urinary 
problems, bothersomeness of urinary symptoms and limitation of activities of daily 
living because of urinary problems. The total BII score ranges from 0 (no symptom 
impact) to 13 (significant symptom impact).  
The PPST questionnaire consists of two questions that assess a subject’s 
perception and satisfaction with the effect of study treatment on control of urinary 
symptoms. Question 1 was ‘Overall, how satisfied are you with the treatment and 
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its effect on your urinary problems?’, and question 2 was ‘Would you ask your 
doctor for the treatment you received in this study?’.  Question 1 was rated on a 
seven-point scale from ‘very satisfied’ to ‘very dissatisfied’. Question 2 was rated 
on a three-point scale of ‘yes’, ‘no’ or ‘not sure’. 
At baseline and months 12 and 24, patients underwent DRE (Digital Rectal 
Exam), blood chemistry analysis, haematology and PSA tests, and urine analysis 
by dipstick. Data on AEs (Adverse Events) were collected from the time of 
administration of the first study treatment dose until discontinuation. 
 
 
4.1.1 Independent Advisory Committee 
An Idependent Advisory Committee will provide ongoing scientific and 
operational oversight to the study. The Committee will evaluate the ongoing study 
outcomes  twice a year. 
 
 
4.2 Study Population 
4.2.1 Inclusion criteria 
1. men aged >=50 years 
2. confirmed clinical diagnosis of BPH and moderate LUTS (IPSS 8-19)  
3. Prostate Volume >= 30ml by TRUS (at screening) 
4. Serum prostate-specific antigen (PSA) level >=1.5 ng/ml 
 
4.2.2 Exclusion criteria 
1. Evidence or suggestion of prostate cancer 
2. Neurogenic bladder dysfunction 
3. History of acute urinary retention necessitating two or more 
catheterizations in the previous 2 years 
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4. History of prostate surgery or other invasive procedure  (e.g. 
transurethral microwave thermotherapy, urethral stenting ,balloon 
urethroplasty) 
5. History of condition predisposing patient to urethral strictures 
6. Chronic bacterial prostatitis 
7. Total serum PSA level of >10ng/ml 
8. Use of drugs with antiandrogenic properties 
9. Hematuria associated with untreated active  urinary tract infection, 
prostatitis or bladder cancer 
10. Current or prior treatment related to BPH 
11. Any condition jeopardizing patient's ability to complete the study 
 
 
4.2.3 Discontinuation of Subjects from treatment 
Subjects should discontinue study treatment for any of the following reasons: 
a) Withdrawal of informed consent (subject’s decision to withraw for any 
reason) 
b) Any clinical AE or intercurrent illness which in opinion of the Investigator, 
indicates that conyinued participation in the study is not in the best interest 
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UNIT 5: STUDY ENDPOINTS & 
STATISTICAL ANALYSIS 
 
5.1 Efficacy Assessments 
 
5.1.1 Primary efficacy endpoint 
The primary efficacy endpoint of the study will be the change in IPSS from 
baseline to month 24. 
 
5.1.2 Secondary efficacy endpoints 
The secondary efficacy endpoints will be the categorical improvements in IPSS ( 
>=3 points or >=25%) and the time to, and proportion of, patients with clinical 
progression of BPH {rise in total IPSS of >=3 points compared with baseline, 
BPH-related AUR, recurrent UTI, overflow or urge incontinence or renal 
insufficiency (single >=50% rise from baseline serum creatinine and total value 
>=1.5mg/dl)}. 
Health outcomes will be include change in BII score from baseline; rating of IPSS-
Q8; and responses to two questions of the PPST questionnaire. 
 
5.2 Safety Assessments 
Safety assessments will include drug-related Adverse Events (AE) and Serious 
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5.3 Statistical Analysis 
 
 5.3.1 Efficacy Analysis 
 
 Primary Efficacy Endpoint 
The primary efficacy endpoint of the study will be the change in IPSS from 
baseline to month 24 (mean IPSS 24th month – mean IPSS baseline). The statistical 
test which is going to be used is t-test for dependent data (paired samples t-test) 
with P-value=0.05 (level of significance) in IBM SPSS Statistics 22. We are going 
to observe if there is statistically significant difference between mean IPSS in 24th 
month vs mean IPSS in baseline . 
  
 
 Secondary Efficacy Endpoint 
 Categorical changes in IPSS 
Categorical improvements in IPSS (patients with improvement >=3 points in IPSS 
or >=25%) between 24th month and baseline are going to be observed with 
Descriptive Statistics using IBM SPSS Statistics 22.   We are going to observe the 
percentage of the patients who will show improvement>=3 points in IPSS or 
>=25% between 24th month and baseline. 
 Clinical progression 
Clinical progression of BPH (patients with symptom progression with rise in total 
IPSS >=3 between 24th month and baseline, BPH-related AUR, BPH- related UTI, 
BPH- related urinary incontinence, BPH- related renal insufficiency) is going to be 
observed with Descriptive Statistics using IBM SPSS Statistics 22.  We are going 
to observe the percentage of the patients (and the cardinal number) who will 
develop clinical progression of BPH between 24th month and baseline. 
 Health outcomes (BII Score, IPSS Q-8 and PPST) 
For BII Score and IPSS Q-8 we are going to observe the change between 24th  
month and baseline (mean BII Score 24th month – mean BII Score baseline and  
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mean IPSS Q8 24th month – mean IPSS Q8 baseline). The statistical test which is 
going to be used is t-test for dependent data (paired samples t-test) with P-
value=0.05 (level of significance) in IBM SPSS Statistics 22. We are going to 
observe if there is statistically significant difference between  mean  BII Score 24th 
month vs BII Score baseline and between mean IPSS Q8 24th month vs IPSS Q8 
baseline . 
The PPST questionnaire consists of two questions that assess a subject’s perception 
and satisfaction with the effect of study treatment on control of urinary symptoms. 
Question 1 was ‘Overall, how satisfied are you with the treatment and its effect on 
your urinary problems?’, and question 2 was ‘Would you ask your doctor for the 
treatment you received in this study?’. Question 1 was rated on a seven-point scale 
from ‘very satisfied’ to ‘very dissatisfied’.    Question 2 was rated on a three-point 
scale of ‘yes’, ‘no’ or ‘not sure’. We are going to exam the percentage of 
thepatients (and the cardinal number) in each category in the baseline and in the 
24th month with Descriptive Statistics using IBM SPSS Statistics 22. 
 
 5.3.2 Safety Analysis 
In this study we are going to record the occurrence of drug-related Adverse Events, 
serious Adverse Events, or Adverse Events leading to study/drug discontinuation 
with Descriptive Statistics using IBM SPSS Statistics 22 . We are going to observe 
the percentage of the patients (and the cardinal number) who will develop AE, 
SAE and Adverse Events leading to study/drug discontinuation using IBM SPSS 
Statistics 22. 
In global bibliography the most commonly drug-related Adverse Events which 
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UNIT 6: ADVERSE EVENTS 
6.1 Definitions 
An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical 
investigation subject administrated a pharmaceutical product and which does not 
necessarily have a casual relationship with this treatment. 
A Serious Adverse Event (SAE) is any untoward medical occurrence that at any 
dose : 
 Results in death 
 Is life-threatening (defined as an event in which the subject was at risk of 
death at the time of the event) 
 Requires inpatient hospitalization or causes prolongation of existing 
hospitalization 
 Results in persistent or significant disability/incapacity 
 Is a congenital anomaly/birth defect 
 Is an important medical event 
 
 
6.2 Severity of Adverse Event 
 Mild (grade 1)- awareness of event but easily tolerated 
 Moderate (grade 2)- discomfort enough to cause some interference with 
usual activity 
 Severe (grade 3)- inability to carry out usual activity 
 Very severe (grade 4)- life-threatening or disabling AE 
 
6.3 Adverse Event Documentation-Reporting 
Subjects must be carefully monitored for AE. All AE occurring after the 
subject has signed the informed consent form must be fully recorded in the 
subject’s CRF. Each event should be described in detail along with start and stop 
dates, severity, relationship to investigational product, action taken and outcome. 
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SAE must immediately (within 24 hours of the investigator’s awareness) be 
reported and must be followed up until resolution or stabilization. If required and 
according to local law and regulations, SAE must be reported  to the Ethics 




An overdose is defined as the accidental or intentional ingestion of any dose of a 
product that is considered both excessive and medically important. All occurrences 





UNIT 7: ADMINISTRATIVE SECTION 
7.1 Compliance with the protocol  
 The study shall be conducted as described in this approved protocol. The 
Investigator should not implement any deviation or change to the protocol without 
prior review and documented approval/favorable opinion from the IRB/IEC of an 
amendment, except where necessary to eliminate an immediate hazard to study 
subjects. Any significant deviation must be documented in the CRF. 
 
7.2 Records Retention 
 The Investigator must retain investigational product disposition records, 
copies of CRFs (or electronic files) and source documents for the maximum period 
required by applicable regulations and guidelines or institution procedures, or for 
the period specified by the sponsor, whichever is longer. If the Investigator 
withdraws from the study (e.g. relocation, retirement) the records shall be 
transferred to a mutually agreed upon designee (e.g. another Investigator). 
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7.3 Case Report Forms 
 An Investigator is required to prepare and maintain adequate and accurate 
case histories designed to record all observations and other data pertinent to the 
investigation on each individual treated in the investigation. Data reported on the 
CRF that are derived from source documents must be consistent with the source 
documents or the discrepancies must be explained. 
 The confidentiality of records that could identify subjects must be protected 
,respecting the privacy and confidentiality rules in accordance with applicable 
regulatory requirements. 
 The Investigator will maintain a signature sheet to document signatures and 
initials of all persons authorized to make entries and/or corrections on CRFs. 
 The completed CRF , including any paper SAE, must be promptly reviewed, 
signed and dated by a qualified physician who is an investigator or subinvestigator. 
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LIST OF ABBREVIATIONS 
 
Term      Definition 
5ARIs     5a-reductase inhibitors 
AE      Adverse Event 
AUR       Acute Urinary Retention 
BPH      Benign prostatic hyperplasia 
BII      BPH- Impact Index  
CRF      Case Report Form 
DHT      Dihydrotestosterone 
DRE      Digital Rectal Exam 
GCP      Good Clinical Practice 
IA      Interim Analysis 
ICH      International Conference of Harmonization  
IEC      International Ethics Committee  
IPSS      International Prostate Symptom Score  
LUTS     Lower Urinary Tract Symptoms 
PPST      Patient Perception of Study Treatment 
PSA      Prostate Specific Antigen 
QoL      Quality of Life  
SAE      Serious Adverse Event 
TRUS     Transrectal Ultrasound 
TURP     Transurethral Prostatectomy  
UTI      Urinary Tract Infection 
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